Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Deals  ·  Weekly Digest 23 August to 29 August 2025
Koas acquires antibody drug developer Novelty Nobility

Weekly Digest – August 2025 Weekly Digest – August 2025 23 August 2025: Koas acquires antibody drug developer Novelty Nobility Koas, Korea’s top office furniture maker, announced a KRW 50 billion investment to acquire Novelty Nobility, making it a subsidiary […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 23 August to 29 August 2025
Indena and TCG GreenChem join forces to advance next-generation ADC technologies

Weekly Digest – August 2025 Weekly Digest – August 2025 28 August 2025: Indena and TCG GreenChem join forces to advance next-generation ADC technologies Indena and TCG GreenChem formed a strategic partnership to accelerate payload–linker development for ADCs  Indena contributes […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 16 August to 22 August 2025
Ifinatamab deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with pretreated extensive stage small cell lung cancer

Weekly Digest – August 2025 Weekly Digest – August 2025 18 August 2025: Ifinatamab deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with pretreated extensive stage small cell lung cancer The U.S. FDA has granted Breakthrough Therapy Designation […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 16 August to 22 August 2025
Izalontamab brengitecan (EGFRxHER3 ADC) granted Breakthrough Therapy Designation by U.S. FDA for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Weekly Digest – August 2025 Weekly Digest – August 2025 18 August 2025: Izalontamab brengitecan (EGFRxHER3 ADC) granted Breakthrough Therapy Designation by U.S. FDA for patients with previously treated advanced EGFR-mutated non-small cell lung cancer The U.S. FDA granted Breakthrough […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 16 August to 22 August 2025
Antengene’s ATG-022 (CLDN18.2 ADC) granted Breakthrough Therapy Designation for the treatment of gastric/gastroesophageal junction adenocarcinoma

Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Antengene’s ATG-022 (CLDN18.2 ADC) granted Breakthrough Therapy Designation for the treatment of gastric/gastroesophageal junction adenocarcinoma Antengene’s CLDN18.2-targeting ADC ATG-022 received Breakthrough Therapy Designation from China’s NMPA for […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 16 August to 22 August 2025
LM-302 (CLDN18.2 ADC), a class 1 new drug, has again been granted Breakthrough Therapy designation, demonstrating global advancement in research and development

Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: LM-302 (CLDN18.2 ADC), a class 1 new drug, has again been granted Breakthrough Therapy designation, demonstrating global advancement in research and development Lixin Pharmaceuticals LM-302 (CLDN18.2 ADC), […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 16 August to 22 August 2025
Mabwell’s CDH17-targeting ADC 7MW4911 receives IND clearance from FDA

Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Mabwell’s CDH17-targeting ADC 7MW4911 receives IND clearance from FDA Mabwell’s CDH17-targeting ADC 7MW4911 received FDA IND clearance to begin Phase 1/2 trials in advanced colorectal cancer and […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 16 August to 22 August 2025
Henlius licenses Phase 3 innovative HER2 ADC from GeneQuantum

Weekly Digest – August 2025 Weekly Digest – August 2025 19 August 2025: Henlius licenses Phase 3 innovative HER2 ADC from GeneQuantum Henlius has licensed exclusive development and commercialization rights for GeneQuantum’s HER2-targeted ADC GQ1005 in China and selected overseas […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest 09 August to 15 August 2025
UAE fast-tracks approval of Blenrep, pioneering treatment for multiple myeloma

Weekly Digest – August 2025 Weekly Digest – August 2025 12 August 2025: UAE fast-tracks approval of Blenrep, pioneering treatment for multiple myeloma The UAE has approved Blenrep (Belantamab Mafodotin) as a treatment for relapsed or resistant multiple myeloma UAE […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 09 August to 15 August 2025
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Weekly Digest – August 2025 Weekly Digest – August 2025 11 August 2025: Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma Junshi Bioscience’s supplemental new drug application (sNDA) for toripalimab […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous363738394041424344Next ›Last »
Page 40 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id